Ignite Creation Date:
2025-12-24 @ 11:07 PM
Ignite Modification Date:
2025-12-25 @ 8:39 PM
Study NCT ID:
NCT01365169
Status:
RECRUITING
Last Update Posted:
2025-08-03
First Post:
2011-06-01
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D013005', 'term': 'Somatostatinoma'}, {'id': 'D015179', 'term': 'Colorectal Neoplasms'}, {'id': 'D007012', 'term': 'Hypopharyngeal Neoplasms'}, {'id': 'D000077274', 'term': 'Nasopharyngeal Carcinoma'}, {'id': 'D009959', 'term': 'Oropharyngeal Neoplasms'}, {'id': 'D007822', 'term': 'Laryngeal Neoplasms'}, {'id': 'D009362', 'term': 'Neoplasm Metastasis'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D018278', 'term': 'Carcinoma, Neuroendocrine'}, {'id': 'D018358', 'term': 'Neuroendocrine Tumors'}, {'id': 'D017599', 'term': 'Neuroectodermal Tumors'}, {'id': 'D009373', 'term': 'Neoplasms, Germ Cell and Embryonal'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D018273', 'term': 'Carcinoma, Islet Cell'}, {'id': 'D010190', 'term': 'Pancreatic Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D004701', 'term': 'Endocrine Gland Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D010182', 'term': 'Pancreatic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}, {'id': 'D010610', 'term': 'Pharyngeal Neoplasms'}, {'id': 'D010039', 'term': 'Otorhinolaryngologic Neoplasms'}, {'id': 'D010608', 'term': 'Pharyngeal Diseases'}, {'id': 'D009057', 'term': 'Stomatognathic Diseases'}, {'id': 'D010038', 'term': 'Otorhinolaryngologic Diseases'}, {'id': 'D009303', 'term': 'Nasopharyngeal Neoplasms'}, {'id': 'D009302', 'term': 'Nasopharyngeal Diseases'}, {'id': 'D007818', 'term': 'Laryngeal Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D009385', 'term': 'Neoplastic Processes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'HEALTH_SERVICES_RESEARCH', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 590}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2011-05-25', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-07', 'completionDateStruct': {'date': '2027-06-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-07-31', 'studyFirstSubmitDate': '2011-06-01', 'studyFirstSubmitQcDate': '2011-06-01', 'lastUpdatePostDateStruct': {'date': '2025-08-03', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2011-06-03', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2027-06-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Study completion (defined as completing the final assessment)', 'timeFrame': 'Up to 7 months after baseline'}, {'measure': 'Physical Activity (PA) Assessment', 'timeFrame': 'Up to 7 days', 'description': 'PA will be measured by two different devices, (1) a consumer-grade wrist-worn device that collects continuous PA data (Fitbit), and (2) a research-grade, hip-worn accelerometer (Actigraph)'}, {'measure': 'ECOG Performance Status', 'timeFrame': 'Up to 2 weeks', 'description': 'Eastern Cooperation Oncology Group (ECOG) is a 6-point performance status scale used to assess performance using PA as a key indicator (e.g., 0 = fully active, 2 = up and about more than 50% of walking hours, 5 = dead) Performance status will be assessed per usual clinical practice and will be recorded in the medical record.'}], 'secondaryOutcomes': [{'measure': 'Correlation between PA data from the Actigraph and Fitbit', 'timeFrame': 'Up to 7 days', 'description': 'Association between PA measured using a Fitbit and PA measured using Actigraph'}, {'measure': "Correlation between patients' ECOG performance status scores and PA data", 'timeFrame': 'Up to 7 days', 'description': "Association between performance status (PS) assesses by the patient's medical oncologist, and PA data"}, {'measure': 'Correlation between PA data and Overall Survivor (OS)', 'timeFrame': 'Up to 7 days', 'description': 'Association between Physical Activity (PA) data and the Overall Survivor (OS) rate'}, {'measure': 'Accrual of Diverse Sample of Cancer-Patients', 'timeFrame': 'Up to 2 weeks'}, {'measure': 'Retention of using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales) among participants.', 'timeFrame': 'Up to 2 weeks'}, {'measure': 'Acceptability of using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales) among participants.', 'timeFrame': 'Up to 2 weeks'}, {'measure': 'Participants ability to activate, set-up, and use the home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales).', 'timeFrame': 'Up to 2 weeks'}, {'measure': 'Adherence to procedures for home-based health monitor devices activation (e.g. Fitbit, Actigraph, CO monitor, weight scales) self-monitoring (e.g. PA, weight), and self-reported data capture by the devices.', 'timeFrame': 'Up to 2 weeks'}, {'measure': 'Successful upload of data from the home-based health monitor devices to the Cyberinfrastructure for Comparative effectiveness Research (CYCORE) for future analysis.', 'timeFrame': 'Up to 2 weeks'}, {'measure': 'CYCORE Data availability for clinicians and researchers in order to be able to daily monitor patients using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales).', 'timeFrame': 'Up to 2 weeks'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Malignant Head and Neck Neoplasm', 'Malignant Neoplasm', 'Metastatic Malignant Neoplasm in the Neck', 'Metastatic Malignant Neoplasm in the Uterine Cervix', 'Pancreatic Adenocarcinoma', 'Pancreatic Neuroendocrine Carcinoma', 'Recurrent Colorectal Carcinoma', 'Stage I Colorectal Cancer AJCC v6 and v7', 'Stage I Hypopharyngeal Carcinoma AJCC v7', 'Stage I Major Salivary Gland Cancer AJCC v7', 'Stage I Nasopharyngeal Carcinoma AJCC v7', 'Stage I Oral Cavity Cancer AJCC v6 and v7', 'Stage I Oropharyngeal Carcinoma AJCC v6 and v7', 'Stage II Colorectal Cancer AJCC v7', 'Stage II Hypopharyngeal Carcinoma AJCC v6 and v7', 'Stage II Major Salivary Gland Cancer AJCC v7', 'Stage II Nasopharyngeal Carcinoma AJCC v7', 'Stage II Oral Cavity Cancer AJCC v6 and v7', 'Stage II Oropharyngeal Carcinoma AJCC v6 and v7', 'Stage IIA Colorectal Cancer AJCC v7', 'Stage IIB Colorectal Cancer AJCC v7', 'Stage IIC Colorectal Cancer AJCC v7', 'Stage III Colorectal Cancer AJCC v7', 'Stage III Hypopharyngeal Carcinoma AJCC v7', 'Stage III Laryngeal Cancer AJCC v6 and v7', 'Stage III Major Salivary Gland Cancer AJCC v7', 'Stage III Nasopharyngeal Carcinoma AJCC v7', 'Stage III Oral Cavity Cancer AJCC v6 and v7', 'Stage III Oropharyngeal Carcinoma AJCC v7', 'Stage IIIA Colorectal Cancer AJCC v7', 'Stage IIIB Colorectal Cancer AJCC v7', 'Stage IIIC Colorectal Cancer AJCC v7', 'Stage IV Colorectal Cancer AJCC v7', 'Stage IVA Colorectal Cancer AJCC v7', 'Stage IVA Hypopharyngeal Carcinoma AJCC v7', 'Stage IVA Laryngeal Cancer AJCC v7', 'Stage IVA Major Salivary Gland Cancer AJCC v7', 'Stage IVA Nasopharyngeal Carcinoma AJCC v7', 'Stage IVA Oral Cavity Cancer AJCC v6 and v7', 'Stage IVA Oropharyngeal Carcinoma AJCC v7', 'Stage IVB Colorectal Cancer AJCC v7', 'Stage IVB Hypopharyngeal Carcinoma AJCC v7', 'Stage IVB Laryngeal Cancer AJCC v7', 'Stage IVB Major Salivary Gland Cancer AJCC v7', 'Stage IVB Nasopharyngeal Carcinoma AJCC v7', 'Stage IVB Oral Cavity Cancer AJCC v6 and v7', 'Stage IVB Oropharyngeal Carcinoma AJCC v7', 'Metastatic or Locally Unresectable Solid Tumor']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://www.mdanderson.org', 'label': 'MD Anderson Cancer Center Website'}]}, 'descriptionModule': {'briefSummary': 'The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and overall survival. The purpose is to advance the evidence-base for incorporating objective assessment of Physical Activity (PA) in the context of performance status assessment in advanced cancer patients.', 'detailedDescription': 'PRIMARY OBJECTIVES:\n\nI. To explore the feasibility and acceptability in diverse samples of cancer patients of wireless collection and transmission of data for transfer into the open-source cyberinfrastructure (CI) called Cyberinfrastructure for Comparative Effectiveness Research (CYCORE).\n\nOUTLINE: Patients are assigned to 1 of 4 arms.\n\nARM I (COLORECTAL CANCER PATIENTS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use two accelerometers, a blood pressure monitor, a heart rate monitor, a global positioning system (GPS) device, and a smart phone that prompts patients to electronically answer questions about exercise and health-related symptoms and feelings. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.\n\nARM II (HEAD AND NECK CANCER PATIENTS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use two accelerometers, a blood pressure monitor, a weight scale, and a smart phone that prompts patients to electronically answer questions about diet and health-related symptoms. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.\n\nARM III (HEAD AND NECK CANCER PATIENTS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use a smart phone that prompts patients to electronically answer questions about diet, health-related symptoms, and swallowing exercises. Patients also take video recordings of their neck while performing swallowing exercises. The device is used for 5 consecutive days. After a 2 week period, patients resume use of the device for an additional 5 days.\n\nARM IV (CANCER SURVIVORS THAT ARE CURRENT/FORMER SMOKERS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use a carbon monoxide (CO) monitor and a smart phone that prompts patients to electronically answer questions about smoking. Patients also take video recordings of themselves while exhaling into the CO monitor. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.\n\nPANCREATIC CANCER STUDY (PCS): Patients receive post-surgical wellness program consisting of physical activity, nutrition counseling, and daily monitoring (physical activity, weight, and self-reported data) for up to 7 months post-op.\n\nTechnological Approach to Performance Status (TAPS) Study: Patients use two Physical Activity monitor devices, the wrist-worn device (Fitbit) continuously and the Actigraph during waking hours. Patients use the devices for 7 consecutive days.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Diagnosis of any stage I - IV colorectal cancer or recurrent colorectal cancer (Arm 1)\n* Able to speak, read, and write in English (Pre-pilot phase, Arms 1-4)\n* Able to provide informed consent (Pre-pilot phase, Arms 1-4, PCS study)\n* Lives in the Houston area (Harris county or a contiguous county) (Pre-pilot phase)\n* Eastern Cooperative Oncology Group (ECOG) status of 0 - 2, or self-reports being up and about more than 50% of waking hours and able to provide self-care (Arm 1)\n* Diagnosis of any of the following cancers: stage 1-4b oropharyngeal, hypopharyngeal, nasopharyngeal, salivary gland or oral cavity; stage 3-4b laryngeal; any unknown primary head and neck cancer with cervical metastasis that will be addressed with treatment to bilateral necks and mucosa; or other head and neck cancers medically approved by one of our Radiation Oncology collaborating medical doctors (MDs) (Arms 2 and 3)\n* History of any cancer, other than non-melanoma skin cancer (Arm 4)\n* Admitted to being a current smoker or recent quitter upon admission to MD Anderson Cancer Center (MDACC) (Arm 4)\n* Has a valid home address and functioning home telephone number (Arm 4)\n* Lives in the Houston or surrounding area, or resides in this same area during the time period that coincides with this study (Arms 1-4)\n* Patients who will undergo curative pancreatectomy for pancreatic adenocarcinoma, pancreatic neuroendocrine tumors, or pancreatic cysts (malignant or benign) (PCS study)\n* Fluent in English (PCS study)\n* Must have telephone access and agree to engage with research personnel using telephone (PCS study)\n* Diagnosis of a metastatic or locally unresectable solid tumor (TAPS study)\n* Fluent in English (TAPS study)\n* Age 18 years or older (TAPS study)\n* ECOG performance status score between 0-3 (TAPS study)\n\nExclusion Criteria:\n\n* Major surgery in the past 8 weeks (Arms 1 and 4)\n* Self-reports hypertension that is not being monitored by a physician and is not being managed with either medication, observation, or lifestyle change (Pre-pilot phase, Arms 1-3)\n* Overt cognitive difficulty demonstrated by not being clearly oriented to time or person or place (Arms 1-4)\n* Orthopedic, neurologic, or musculoskeletal disability that would interfere with the functional task of standing on a weight scale (Pre-pilot phase, Arm 2)\n* Not currently receiving radiation treatment for a cancer listed in the arm-specific inclusion criteria (Arms 2 and 3)\n* Zubrod performance status \\> 2, or self-reports either not being up and about more than 50% of waking hours or unable to provide self-care (Arms 2 and 3)\n* Currently receiving treatment for a cancer other than those listed in the arm-specific inclusion criteria (exception: the study does not exclude those receiving treatment for non-melanoma skin cancer) (Arms 2 and 3)\n* History of current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g. dysphagia due to underlying neurogenic disorder) (Arm 3 only)\n* Active substance use disorder (diagnosed or strongly suspected) (Arm 4)\n* Currently enrolled in protocol 2014-0712 (PCS study)\n* No home access to internet (PCS study)\n* No home WiFi connection (PCS study)\n* During clinician's pre-surgical evaluation, presents with high risk for non-therapeutic resection related to cancer diagnosis (PCS study)\n* Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV) (PCS study)\n* Recent fracture or acute musculoskeletal injury that precludes the ability to fully bear weight on all 4 limbs in order to participate in an exercise intervention (PCS study)\n* Poorly-controlled pain with a self-reported pain score of 7/10 at the time of enrollment (PCS study)\n* Myopathic or rheumatologic disease that impacts physical function (PCS study)\n* Has a pacemaker or other internal medical device, or reports being pregnant (PCS study)\n* Currently enrolled in protocol 2017-0198 (PCS study)\n* Demonstration of overt cognitive difficulty as demonstrated by not being clearly oriented to time or person or place (TAPS study)"}, 'identificationModule': {'nctId': 'NCT01365169', 'briefTitle': 'Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"', 'organization': {'class': 'OTHER', 'fullName': 'M.D. Anderson Cancer Center'}, 'officialTitle': '"CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial"', 'orgStudyIdInfo': {'id': '2010-0955'}, 'secondaryIdInfos': [{'id': 'NCI-2014-02468', 'type': 'REGISTRY', 'domain': 'CTRP (Clinical Trial Reporting Program)'}, {'id': '2010-0955', 'type': 'OTHER', 'domain': 'M D Anderson Cancer Center'}, {'id': 'R01CA243554', 'link': 'https://reporter.nih.gov/quickSearch/R01CA243554', 'type': 'NIH'}, {'id': 'RC2CA148263', 'link': 'https://reporter.nih.gov/quickSearch/RC2CA148263', 'type': 'NIH'}, {'id': 'R01CA177996', 'link': 'https://reporter.nih.gov/quickSearch/R01CA177996', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Arm I (colorectal cancer patients)', 'description': '(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a heart rate monitor, a GPS device, and a smart phone that prompts patients to electronically answer questions about exercise and health-related symptoms and feelings. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.', 'interventionNames': ['Other: Health Telemonitoring', 'Other: Questionnaire Administration']}, {'type': 'EXPERIMENTAL', 'label': 'Arm II (head and neck cancer patients)', 'description': '(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a weight scale, and a smart phone that prompts patients to electronically answer questions about diet and health-related symptoms. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.', 'interventionNames': ['Other: Health Telemonitoring', 'Other: Questionnaire Administration']}, {'type': 'EXPERIMENTAL', 'label': 'Arm III (head and neck cancer patients)', 'description': '(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a smart phone that prompts patients to electronically answer questions about diet, health-related symptoms, and swallowing exercises. Patients also take video recordings of their neck while performing swallowing exercises. The device is used for 5 consecutive days. After a 2 week period, patients resume use of the device for an additional 5 days.', 'interventionNames': ['Other: Health Telemonitoring', 'Other: Questionnaire Administration']}, {'type': 'EXPERIMENTAL', 'label': 'Arm IV (cancer survivors that are current/former smokers)', 'description': '(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a CO monitor and a smart phone that prompts patients to electronically answer questions about smoking. Patients also take video recordings of themselves while exhaling into the CO monitor. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.', 'interventionNames': ['Other: Health Telemonitoring', 'Other: Questionnaire Administration']}, {'type': 'EXPERIMENTAL', 'label': 'PCS (pancreatic surgery patients)', 'description': 'Patients receive post-surgical wellness program consisting of physical activity, nutrition counseling, and daily monitoring (physical activity, weight, and self-reported data) for up to 7 months post-op.', 'interventionNames': ['Behavioral: Exercise Intervention', 'Other: Health Telemonitoring', 'Other: Quality-of-Life Assessment', 'Other: Questionnaire Administration']}, {'type': 'EXPERIMENTAL', 'label': 'TAPS (Technological Approach to Performance Status)', 'description': 'Patients use two Physical Activity monitor devices, the wrist-worn device (Fitbit) continuously and the Actigraph during waking hours. Patients use the devices for 7 consecutive days.', 'interventionNames': ['Other: Health Telemonitoring']}], 'interventions': [{'name': 'Exercise Intervention', 'type': 'BEHAVIORAL', 'description': 'Participate in walking and/or strengthening program', 'armGroupLabels': ['PCS (pancreatic surgery patients)']}, {'name': 'Health Telemonitoring', 'type': 'OTHER', 'description': 'Use accelerometers, blood pressure monitor, heart rate monitor, GPS device, and smart phone', 'armGroupLabels': ['Arm I (colorectal cancer patients)']}, {'name': 'Health Telemonitoring', 'type': 'OTHER', 'description': 'Use accelerometers, blood pressure monitor, weight scale, and smart phone', 'armGroupLabels': ['Arm II (head and neck cancer patients)']}, {'name': 'Health Telemonitoring', 'type': 'OTHER', 'description': 'Use smart phone', 'armGroupLabels': ['Arm III (head and neck cancer patients)']}, {'name': 'Health Telemonitoring', 'type': 'OTHER', 'description': 'Use CO monitor and smart phone', 'armGroupLabels': ['Arm IV (cancer survivors that are current/former smokers)']}, {'name': 'Health Telemonitoring', 'type': 'OTHER', 'description': 'Use Fitbit, weight scale and iPhone- or web-based app for self-reported data', 'armGroupLabels': ['PCS (pancreatic surgery patients)']}, {'name': 'Quality-of-Life Assessment', 'type': 'OTHER', 'otherNames': ['Quality of Life Assessment'], 'description': 'Ancillary studies', 'armGroupLabels': ['PCS (pancreatic surgery patients)']}, {'name': 'Questionnaire Administration', 'type': 'OTHER', 'description': 'Ancillary studies', 'armGroupLabels': ['Arm I (colorectal cancer patients)', 'Arm II (head and neck cancer patients)', 'Arm III (head and neck cancer patients)', 'Arm IV (cancer survivors that are current/former smokers)', 'PCS (pancreatic surgery patients)']}, {'name': 'Health Telemonitoring', 'type': 'OTHER', 'description': 'Use Fitbit and Actigraph', 'armGroupLabels': ['TAPS (Technological Approach to Performance Status)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Susan K. Peterson', 'role': 'CONTACT', 'phone': '713-792-8267'}, {'name': 'Susan K. Peterson', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'M D Anderson Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}], 'centralContacts': [{'name': 'Susan Peterson', 'role': 'CONTACT', 'email': 'speterso@mdanderson.org', 'phone': '713-792-8267'}], 'overallOfficials': [{'name': 'Susan K Peterson', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'M.D. Anderson Cancer Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'M.D. Anderson Cancer Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR'}}}}